ClinicalTrials.gg
RecruitingNCT07172477SPACERUpdated Nov 17, 2026

Early Phase Study Using the 'Pivot Extend' System as a Treatment for Patients With Tricuspid Regurgitation

An interventional study of Pivot Extend in Tricuspid Regurgitation, sponsored by Tau Medical Australia Pty Ltd. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Tau Medical Australia Pty Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Participants with severe tricuspid regurgitation may require heart surgery to repair or replace the tricuspid valve. However, there is a high risk associated with these surgeries and it is often not feasible for elderly patients or those with other medical conditions.

The goal of this clinical investigation is

  • To assess the safety of the investigational device "Pivot Extend" in participants aged 18 years or over with severe and clinically symptomatic Tricuspid Regurgitation (TR) deemed suitable for percutaneous valve intervention
  • To evaluate device success, procedural success and clinical outcomes in improving TR symptoms following implantation of the "Pivot Extend" device
02

Conditions studied

  • Tricuspid Regurgitation

Keywords

  • Tricuspid Regurgitation
  • SPACER
  • Pivot Extend
03

In context

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

This study's planned enrollment of 10 is below the median of 60 across 129 interventional studies indexed under Tricuspid Valve Insufficiency.

Browse Tricuspid Valve Insufficiency studies →

Lead sponsor

Tau Medical Australia Pty Ltd is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has voluntarily decided to participate in this clinical trial and has provided written
  • Adults aged 18 years or older at the time of informed consent
  • Has symptoms of TR corresponding to at least Class II, despite receiving optimal medical therapy for at least 30 days prior to screening
  • Meets the criteria at least severe (3+) on the TR grade classification table on echocardiography performed at the screening visit
  • Deemed suitable for percutaneous valve intervention by a Heart Team that includes at least one cardiologist and one cardiac surgeon
  • Is able to understand and follow the investigator's instructions and is able to participate for the entire duration of the study

Exclusion criteria

Exclusion Criteria:

  • Has blood clots, emboli, masses, or growths in the vascular system of the heart or lungs on an echocardiogram and cardiac CT scan performed at the screening visit
  • Uncorrected blood clotting disorders based on hematology tests performed at the screening visit
  • Unable to use anticoagulant agents (NOAC ex.Xarelto)
  • A history of major bleeding (excluding minor bleeding such as nosebleed that can be hemostasized) treated with anticoagulants at any time prior to participation in this clinical trial
  • Severe anemia ( less than or equal to 80g/L)
  • Has an implanted device such as an implantable cardioverter defibrillator (ICD) or pacemaker
  • Has anatomy that, in the opinion of the investigator, is not suitable for implantation of an medical device based on echocardiogram and cardiac CT scan performed at the screening visit
  • Requires surgery or interventional procedures (coronary artery bypass graft (CABG) or surgery for atrial septal defect (ASD)) based on an echocardiogram performed at the screening visit
  • count of 50 x 10\^9 per litre of blood or less based on hematology tests performed at the screening visit
  • Pulmonary arterial hypertension, defined as pulmonary artery systolic pressure greater than 70mmHg on cardiac catheterization performed at the screening visit, or a pulmonary vascular resistance greater than 3 Wood Units on right heart catheterization
  • (LVEF) of less than 20% on echocardiogram performed at the screening visit
  • Active gastrointestinal bleeding or a digestive procedure within 90 days prior to screening for this study, and/or those with the potential for gastrointestinal bleeding in the opinion of the investigator
  • History of cerebrovascular accident (CVA) or (TIA) within 30 days prior to screening for this clinical trial
  • History of myocardial infarction (MI) within 30 days prior to screening for this study
  • Active endocarditis requiring antibiotic treatment
  • or end-stage renal failure requiring hemodialysis and other chronic conditions with a of less than one year
  • Moderate or severe aortic, pulmonary artery, or mitral stenosis on echocardiogram performed at the screening visit
  • Severe or greater mitral valve regurgitation or severe aortic valve regurgitation as determined by echocardiographic grading criteria at the screening visit
  • Calcification of the tricuspid valve leaflets affecting the procedure on an echocardiogram performed at the screening visit
  • Those who have participated in another clinical trial within 30 days prior to screening for this clinical trial
  • Pregnant or breastfeeding, or planning to become pregnant during the clinical trial period
  • Participants of who are not using a highly effective method of
  • Coexisting condition, which most likely limits the life expectancy to less than one year
  • Preexisting pulmonary valve prosthesis or a right ventricle to pulmonary artery (RV-PA) conduit
  • Any other clinical findings that, in the opinion of the investigator, are medically inappropriate for this clinical trial
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Pivot Extend device

    Patients aged 18 years or older with severe and symptomatic tricuspid regurgitation

    Device: Pivot Extend

Interventions

  • DevicePivot Extend

    The investigational "Pivot Extend" device will be inserted through a small incision in the femoral vein and guided to the heart using a catheter. The Pivot Extend device is designed to sit in the space where the valve isn't closing, helping the flaps of the valve to close tightly and reducing the amount of blood leaking back through the valve.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety of the implantation of the "Pivot Extend" device

    Occurrence rate of major adverse cardiac events (MACE) (e.g. stroke, myocardial infarction, pulmonary embolism)

    Time frame: 30 days post device implantation

Secondary outcomes

  1. To evaluate the Pivot Extend device success

    Rate of successful device placement at target location

    Time frame: During implantation procedure

  2. To evaluate the procedural success (1)

    The number of participants who experienced at least 1 drop in their TR grade from screening, based on echocardiographic assessment

    Time frame: 30 days, 180 days and 365 days post device implantation

  3. To evaluate the procedural success (2)

    Changes in echocardiogram (measurements and assessments of the heart's structure and function) as assessed by the central "Core Lab" reader

    Time frame: 30 days, 180 days and 365 days post device implantation

  4. To evaluate the procedural success (3)

    Occurrence rate of MACE associated with the device or procedure

    Time frame: 180 and 365 days after device implantation

  5. To evaluate the procedural success (4)

    Changes in Computed Tomography (CT) images (evaluating the size, shape and function of the tricuspid valve following Pivot Extend device insertion) as assessed by the central "Core Lab" reader.

    Time frame: 30 days, 180 days and 365 days post device implantation

  6. To evaluate the clinical outcomes (1)

    Changes in right ventricular volume from baseline, assessed by cardiac computed tomography (CT)

    Time frame: 180 days and 365 days post device implantation

  7. To evaluate the clinical outcomes (2)

    Changes in echocardiogram (measurements and assessments of the heart's structure and function) as assessed by the central "Core Lab" reader

    Time frame: 180 days and 365 days post device implantation

  8. To evaluate the clinical outcomes (3)

    Number of participants with improvement in New York Heart Association (NYHA) functional class (system to classify the severity of heart failure symptoms) from baseline

    Time frame: 30 days, 180 days and 365 days post device implantation

  9. To evaluate clinical outcomes (4)

    Measure in the changes of distance travelled during a 6 Minute Walk Test from baseline

    Time frame: 30 days, 180 days and 365 days post device implantation

  10. To evaluate clinical outcomes (5)

    Changes in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) score (a measure of symptoms, physical limitation, social limitations and quality of life domains) from baseline. Participants will be asked to tick a box on a scale indicating how each domain affects their life (e.g. scales range from extremely limited to not at all limited, from every morning/night to never over the past 2 weeks, from completely dissatisfied to completely satisfied). The responses will be used to calculate an average score on a scale of 0 to 100. A higher score equates to better outcomes (i.e. fewer symptoms, better physical and social function, improved quality of life).

    Time frame: 30 days, 180 days and 365 days post device implantation

  11. To evaluate clinical outcomes (6)

    Number of participants with at least 1 level of improvement in pitting edema from baseline

    Time frame: 30 days, 180 days and 365 days post device implantation

  12. To evaluate clinical outcome measures (7)

    Changes in eGFR (estimated glomerular filtration rate) from baseline

    Time frame: 30 days, 180 days and 365 days post device implantation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 24 months is below that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Apr 2026 → Nov 2027 and completion Mar 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Sep 15, 2025
StartActual
Nov 11, 2025
Primary completionEst.
Nov 30, 2027was Apr 2026
CompletionEst.
Feb 2028was Mar 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 2026→Nov 30, 2027
Nov 17, 2026
Study completion
Mar 2027→Feb 2028
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Apr 2026→Nov 30, 2027
    Study completion Mar 2027→Feb 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07172477
Lead sponsor
Tau Medical Australia Pty Ltd
Collaborators
Tau-MEDICAL Co., Ltd.
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Nov 11, 2025
Primary completion
Nov 30, 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Alex (Jongyoon) Park
Contact
jypark@tau-medical.com
+82-(51)515-8783
June-Hong Kim, PhD
study director · Tau-MEDICAL Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion